For the quarter ending 2025-09-30, NVAX had $14,375K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -202,379 | 625,154 |
| Depreciation and amortization | 6,585 | 15,903 |
| Impairment of long-lived assets | - | 349 |
| Non-cash stock-based compensation | 8,549 | 19,499 |
| Provision for excess and obsolete inventory | 566 | 1,379 |
| Impairment of assets held for sale | 97,038 | - |
| Impairment of long-lived assets | 3,382 | - |
| Loss on debt extinguishment | -28,714 | - |
| Other items, net | 229 | -4,682 |
| Inventory | 3,753 | 1,635 |
| Accounts receivable, prepaid expenses, and other assets | -207,927 | 94,947 |
| Accounts payable, accrued expenses, and other liabilities | -26,535 | -274,488 |
| Deferred revenue | -11,712 | -608,860 |
| Net cash provided by (used in) operating activities | 107,804 | -312,964 |
| Capital expenditures | 2,017 | 1,467 |
| Purchases of available-for-sale marketable securities | 235,012 | 114,724 |
| Proceeds from maturities of available-for-sale marketable securities | 100,500 | 154,625 |
| Internal-use software | 0 | 655 |
| Net cash provided used in investing activities | -136,529 | 37,779 |
| Net proceeds from sales of common stock | 0 | 0 |
| Proceeds on the issuance of convertible senior notes due 2031, net of issuance costs | 42,606 | - |
| Net proceeds from the exercise of stock-based awards | 820 | -5,288 |
| Finance lease payments | 984 | 2,813 |
| Net cash provided by financing activities | 42,442 | -8,101 |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | 658 | 6,976 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 14,375 | -276,310 |
| Cash and cash equivalents at beginning of period | 545,292 | - |
| Cash and cash equivalents at end of period | 283,357 | - |
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)